CD22 and neoplasm: One particular format targets the cytotoxic potential of immune effector cells (IECs) by bridging an activating receptor on IEC (e.g., CD3ε on T cells) and an antigen (e.g., CD22) on malignant cells for subsequent tumor cell lysis [212,213].